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Abstract
Background: Strong evidence supports administration of magnesium sulphate prior to birth at less than 30 weeks’
gestation to prevent very preterm babies dying or developing cerebral palsy. This study was undertaken as part of
The WISH (Working to Improve Survival and Health for babies born very preterm) Project, to assess health
professionals’ self-reported use of antenatal magnesium sulphate, and barriers and enablers to implementation of
2010 Australian and New Zealand clinical practice guidelines.
Methods: Semi-structured, one-to-one interviews were conducted with obstetric and neonatal consultants and
trainees, and midwives in 2011 (n = 24) and 2012–2013 (n = 21) at the Women’s and Children’s Hospital, South
Australia. Transcribed interview data were coded using the Theoretical Domains Framework (describing 14 domains
related to behaviour change) for analysis of barriers and enablers.
Results: In 2012–13, health professionals more often reported ‘routinely’ or ‘sometimes’ administering or advising
their colleagues to administer magnesium sulphate for fetal neuroprotection (86 % in 2012–13 vs. 46 % in 2011).
‘Knowledge and skills’, ‘memory, attention and decision processes’, ‘environmental context and resources’, ‘beliefs
about consequences’ and ‘social influences’ were key domains identified in the barrier and enabler analysis.
Perceived barriers were the complex administration processes, time pressures, and the unpredictability of preterm
birth. Enablers included education for staff and women at risk of very preterm birth, reminders and ‘prompts’,
simplified processes for administration, and influential colleagues.
Conclusions: This study has provided valuable data on barriers and enablers to implementing magnesium sulphate
for fetal neuroprotection, with implications for designing and modifying future behaviour change strategies, to
ensure optimal uptake of this neuroprotective therapy for very preterm infants.
Background
Preterm birth (birth at less than 37 completed weeks’ gesta-
tion), accounts for three quarters of perinatal mortality and
over half of long-term morbidity [1]. While survival rates
for preterm infants have increased substantially over time,
infants remain at risk of a wide range of complications in
the neonatal period and in the long-term, including neuro-
developmental impairments such as cerebral palsy [1, 2].
Cerebral palsy is the most common physical disability in
childhood, with an estimated prevalence of around two per
1000 live births in Australia; despite research and clinical
advances, its incidence remains stable [3]. There is a clear
and established association between cerebral palsy and pre-
term birth, with over 40 % of individuals with cerebral palsy
born preterm [3]. Accordingly, prevention of cerebral
palsy for infants born preterm is of high interest, with
* Correspondence: emily.bain@adelaide.edu.au
1Australian Research Centre for Health of Women and Babies, Robinson
Research Institute, Discipline of Obstetrics and Gynaecology, School of
Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Full list of author information is available at the end of the article
© 2015 Bain et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Bain et al. BMC Pregnancy and Childbirth  (2015) 15:176 
DOI 10.1186/s12884-015-0618-9
questions relating to prevention identified as research prior-
ities by consumers, clinicians and researchers [4].
Over two decades ago, a case control study described
an association between maternal receipt of magnesium
sulphate and a reduction in cerebral palsy for very low
birthweight infants [5]. Subsequent to this and other ob-
servational studies, five randomised controlled trials
were conducted assessing antenatally administered mag-
nesium sulphate for preventing cerebral palsy [6–10].
These five trials were included in a Cochrane systematic
review, which confirmed benefit, showing that 63 mothers
need to be given magnesium sulphate prior to very pre-
term birth to prevent one case of cerebral palsy [11]. In
response to these findings, in many countries, profes-
sional bodies have recommended this therapy. In 2010
an Australian and New Zealand Guideline Development
Panel prepared and published National Health and
Medical Research Council (NHMRC) endorsed clinical
practice guidelines (see Additional file 1) [12]. Even with
these guidelines, however, it was not anticipated that
health professionals would immediately begin using this
therapy without some form of active implementation
[13, 14]. Based on knowledge of interventions likely to
increase uptake of evidence into obstetric practice, an im-
plementation project WISH (Working to Improve Survival
and Health for babies born very preterm) was planned, and
funded by the Cerebral Palsy Alliance Research Foundation
[15]. This Project is ongoing and comprises a package of ac-
tive implementation strategies to guide the introduction
and local adaptation of guideline recommendations, and to
monitor and improve uptake and health outcomes [15].
While interventions to assist implementing evidence
into obstetric practice have been identified [16], recog-
nising and targeting local, context specific barriers and
enablers is important for successful knowledge transla-
tion. Implementation researchers have highlighted bene-
fits of identifying the theoretical domains that are
causally related to behaviours to assist with appropriately
targeting interventions [17, 18]. Through consensus, be-
havioural experts have identified a set of 14 domains
within a Theoretical Domains Framework (TDF) that
may be considered when assessing implementation
problems and used as a basis for intervention develop-
ment (see Table 1) [17, 18]. These domains have been
used to understand implementation difficulties across a
range of healthcare settings and conditions, such as in
the assessment of barriers and enablers to implementing
preconception care guidelines by general practitioners
[19], pregnancy weight management and obesity guide-
lines by health professionals [20], and for engaging with
pregnant women about stopping smoking [21]. These the-
oretical domains can potentially be used to identify aspects
of health professionals’ behaviour, which can be targeted
to promote use of antenatal magnesium sulphate for fetal
neuroprotection in line with guideline recommendations.
In parallel to this study, as part of The WISH Project,
we have been examining the local uptake of antenatal
magnesium sulphate before and following publication of
Table 1 Domains of the theoretical domains framework, adapted from Cane et al. [17]
Domain Definition
1 Knowledge An awareness of the existence of something
2 Skills An ability or proficiency acquired through practice
3 Social/professional role and identity A coherent set of behaviours and displayed personal quality of an individual in a social or
work setting
4 Beliefs about capabilities Acceptance of the truth, reality, or validity about an ability, talent or facility that a person
can put to constructive use
5 Optimism The confidence that things will happen for the best or that desired goals will be attained
6 Beliefs about consequences Acceptance of the truth, reality, or validity about outcomes of a behaviour in a given situation
7 Reinforcement Increasing the probability of a response by arranging a dependent relationship, or contingency,
between the response and a given stimulus
8 Intentions A conscious decision to perform a behaviour or a resolve to act in a certain way
9 Goals Mental representations of outcomes or end states that an individual wants to achieve
10 Memory, attention and decision processes The ability to retain information, focus selectively on aspects of the environment and
choose between two or more alternatives
11 Environmental context and resources Any circumstance of a person’s situation or environment that discourages or encourages the
development of skills and abilities, independence, social competence, and adaptive behaviour
12 Social influences Those interpersonal processes that can cause individuals to change their thoughts, feelings,
or behaviours
13 Emotion A complex reaction pattern, involving experiential, behavioural, and physiological elements,
by which the individual attempts to deal with a personally significant matter or event
14 Behavioural regulation Anything aimed at managing or changing objectively observed or measured actions
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the NHMRC endorsed guidelines at a tertiary maternity
hospital, the Women’s and Children’s Hospital (WCH)
in South Australia [22]. The aims of this study were to
assess health professionals’ self-reported use and know-
ledge of bi-national guidelines for antenatal magnesium
sulphate for fetal neuroprotection over time, and to ex-
plore local barriers and enablers to implementation
using theoretical domains related to behaviour change.
Methods
Design
Semi-structured interviews, with analysis of barriers and
enablers guided by the TDF [17].
Participants and setting
Participants were obstetric and neonatal consultants and
trainee medical officers, as well as midwives at the
WCH. The first phase of interviews was conducted from
May to August 2011 (following publication of the
NHMRC endorsed guidelines in March 2010 and prior to
dissemination of The WISH Project materials), and the
second phase of interviews was undertaken between
August 2012 and February 2013. The WCH is the largest
tertiary maternity centre in Adelaide, South Australia, with
almost 5000 births per annum and a 14 bed Neonatal
Intensive Care Unit, which is responsible for providing in-
tensive care to babies born at the WCH, elsewhere in
South Australia, and at times, the Northern Territory,
Western Victoria and far west of New South Wales,
Australia [23].
Procedure
For both time periods, contact details of consultant and
trainee obstetricians, neonatologists and midwives were
obtained and numbered consecutively. In 2011, it was
pre-specified that ten obstetricians, eight midwives, and
six neonatologists would be interviewed (from totals of
62, 82 and 20 respectively). Sets of random numbers
were computer-generated and the corresponding individ-
uals invited to participate via email. In 2012–13 it was
similarly pre-specified that ten obstetricians, eight mid-
wives and six neonatologists would be interviewed (from
total numbers of 64, 53 and 20 respectively) (the total
number of midwives decreased in 2012–13, as contact de-
tails of those rostered to the postnatal ward were not pro-
vided). If an individual declined, an additional random
number was computer-generated and the corresponding
staff member was invited to participate. In the case where
an individual who participated in 2011 was again ran-
domly selected in 2012–13, a further random number was
computer-generated. Staff wishing to participate opted
into the study by signing a consent form for recording of
interviews and use of anonymised quotations.
Participants took part in single interviews with one of
five researchers (EB, EVR, LS, SR, TB). Four of the inter-
viewers (EB, EVR, LS, TB) were health researchers who
were not employed by the WCH and did not work on a
day-to-day basis with the participants. External to her
research role, SR was employed as an obstetric trainee
medical officer. Where possible, interviews were con-
ducted face-to-face in a research office within the hos-
pital or within participants’ work offices (two interviews
were conducted by telephone). An interview schedule
with questions guided the discussion. The interviews
were audio-taped and transcribed verbatim. Transcrip-
tions were cross-checked against the recordings for ac-
curacy and de-identification.
Interview schedule
The interview schedule (see Additional file 2) was de-
veloped primarily to elicit responses about health pro-
fessionals’ self-reported use and knowledge of the 2010
bi-national clinical practice guidelines, and barriers and en-
ablers to implementation. Participants were first asked to
describe their position and experience (length of service).
Participants were then asked a series of closed and open-
ended questions to explore their and their colleagues’ prac-
tices regarding administration or advising administration of
antenatal magnesium sulphate, their knowledge of guideline
recommendations, benefits of therapy, and concerns re-
garding adverse effects. Participants were asked to consider
barriers and enablers to implementation, and views regard-
ing possible solutions or ways forward. The interview
schedule was piloted with three health professionals (one
obstetrician, one neonatologist, and one midwife) prior to
data collection to assess its practicability and acceptability.
Analysis
Participants’ responses to questions relating to their
knowledge and use of antenatal magnesium sulphate, its
benefits and adverse effects, were coded and have been
summarised narratively and using percentages. The re-
sponses were summarised across all professional groups,
given that no apparent differences between groups were
observed. Content analysis related to barriers and en-
ablers was conducted following a framework approach
[24], and guided by the TDF [17]. The generated themes
correlated strongly with the domains (see Table 1) [17],
and as such, relevant participant responses/quotes were
coded by domain, and copied and pasted into an Excel
spreadsheet of domains, stratified by professional group
and whether the statement related to a perceived barrier,
enabler or both. The spreadsheets were reviewed and
statements compared between and across domains, pro-
fessional groups, and the two study periods. Two investi-
gators (EB and TB) read and re-read all of the transcripts,
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and independently coded these. The analysis was dis-
cussed between researchers to reach agreement.
Ethics
This study was approved by the WCH Children, Youth
and Women’s Health Service Human Research Ethics
Committee (REC2304/8/13).
Results
In 2011, 24 health professionals participated: ten obstetri-
cians, eight midwives and six neonatologists; in 2012–13,
there were 21 participants: eight obstetricians, eight mid-
wives and five neonatologists. In 2011, one midwife de-
clined participation, and in 2012–13, one obstetric
consultant and one neonatal trainee declined. In 2012–13,
there were three fewer participants than original planned
(with one less neonatal trainee, obstetric trainee and ob-
stetric consultant) due to difficulties contacting those par-
ticipants and scheduling interview times. Final participant
characteristics are summarised in Table 2. Interviews were
of mean 12 ± 5 min duration (range 6 to 26 min).
Knowledge and use of antenatal magnesium sulphate
Participants in 2012–13, compared with those in 2011,
were more likely to report that they ‘Routinely’ or ‘Some-
times’ administered or advised their colleagues to adminis-
ter antenatal magnesium sulphate for fetal neuroprotection
(Fig. 1). All participants (21/21) in 2012–13 and 92 %
(22/24) in 2011 believed that their colleagues adminis-
tered/advised administration of this therapy. The ma-
jority of participants in 2012–13 (17/21, 85 %) and
2011 (18/24, 75 %) reported being aware of the bi-national
clinical practice guidelines. In 2012–13, compared with in
2011, participants were more often able to correctly cite
specific bi-national guideline recommendations regarding
dosage, timing prior to birth, gestational age, and reason(s)
for preterm birth (see Fig. 2).
Benefits and adverse effects of antenatal magnesium
sulphate
In both 2012–13 and 2011 over half of participants spe-
cifically discussed ‘brain protection’ or ‘neuroprotection’,
and/or a reduction in cerebral palsy as benefits of ante-
natal magnesium sulphate therapy (see Fig. 3). Across
both time periods, very few participants cited a com-
bined reduction in neonatal death and cerebral palsy as
a benefit of treatment.
In 2012–13 approximately one fifth of participants
expressed that they had concern regarding adverse ef-
fects of therapy, compared with approximately one third
in 2011. Though often not ‘of concern’, a number of par-
ticipants cited possible adverse effects for the mother,
however far fewer (and predominately neonatologists)
discussed potential neonatal or infant adverse effects
(see Fig. 4).
Table 2 Participant characteristics
Participant group Total Length of service at WCH (years)
<1 1–5 5–10 >10
2011 24
Obstetrician Consultant 5 2 3
Trainee medical officer 5 4 1
Neonatologist Consultant 3 1 1 1
Trainee medical officer 3 1 1 1
Midwife 8 1 1 6
2012–13 21
Obstetrician Consultant 4 2 2
Trainee medical officer 4 4
Neonatologist Consultant 3 1 2
Trainee medical officer 2 1 1
Midwife 8 1 1 6
WCH Women’s and children’s hospital
Fig. 1 Summary of answers by year to the question: ‘Do you
administer (or advise your colleagues to administer) magnesium
sulphate to women at risk of preterm birth?
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Barriers and enablers
Barriers and enablers to the use of antenatal magnesium
sulphate for fetal neuroprotection across both time pe-
riods, as perceived by obstetricians, neonatologists and
midwives, were primarily related to theoretical domains:
‘knowledge’, ‘skills’, ‘memory, attention and decision pro-
cesses’, ‘environmental context and resources’, ‘beliefs
about consequences’, and ‘social influences’. These do-
mains are discussed first, followed by domains that were
less prominent: ‘professional role and identity’ and
‘reinforcement’. Statements depicting the theme for each
domain have been chosen accordingly. Only those theor-
etical domains found to be relevant are presented.
Knowledge and skills
The closely aligned theoretical domains ‘knowledge’ and
‘skills’ refer to whether individuals are aware of an inter-
vention, and their ability (acquired through practice) to
perform the intervention. Across both time periods
(2011 and 2012–13), each professional group cited infor-
mation dissemination to increase knowledge of and skills
for the use of magnesium sulphate for fetal neuroprotec-
tion (such as through in-service training and pamphlets/
brochures for health professionals and women) as a key
enabler. In 2011, several staff members highlighted lack
of awareness as a barrier: “I guess just that everybody,
you know, has this information, which I obviously didn’t.”
(MW6-2011).
In 2011, each professional group identified a need for
staff education, and also education for pregnant women
at risk of giving birth very preterm:
“it’s really education… [for] those who might be in a
position to manage a woman at risk of having an
extremely preterm baby… for physicians and
midwives… and also education for pregnant women”
(CN2-2011).
In regards to skills, in 2011, unfamiliarity with the
medication was identified as a potential barrier. Corres-
pondingly, training was identified, particularly by mid-
wives and also by neonatologists, as an enabler.
In 2012–13, there was recognition, particularly by
midwives, of increased knowledge and skills for appro-
priate administration:
“I think we were a bit gung ho initially, whereas now
we’ve got a better understanding of it… I just think
we’re better at recognising and administering it”
(MW2-2012/13).
Each professional group discussed continued educa-
tion, to reinforce knowledge, as enabling, and empha-
sised the need for education for new groups of staff:
“… it just has to be ongoing education and more
awareness… it’s a continuing process, isn’t it? With
more new staff, at all levels starting from midwives, to
new registrars, and among consultants” (TN2-2012/13).
During 2012–13, a number of midwives similarly
highlighted the importance of educating women at risk
of very preterm birth.
Memory, attention and decision processes
This theoretical domain relates to the factors that influ-
ence whether an individual remembers and chooses to
Fig. 2 Summary by year indicating percentage of participants that
correctly specified antenatal magnesium sulphate guideline
recommendations (regarding: dose, timing, gestational age, and
reasons for preterm birth)
Fig. 3 Summary by year indicating percentage of participants who
specified neuroprotection/brain protection, reductions in cerebral
palsy and death as benefits of antenatal magnesium sulphate
Fig. 4 Summary by year indicating percentage of participants who
were concerned about and/or who specifically mentioned maternal
and/or neonatal/infant adverse effects of antenatal
magnesium sulphate
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engage in an intervention. Across both time periods staff
from each professional group, and particularly obstetri-
cians, highlighted not “thinking of it”, or not “remember-
ing it” as a barrier. “Forgetting” was often perceived to be
a consequence of being in a ‘rush’, or infrequent use:
“You know what the biggest problem is… to remember
to do it… sometimes we’re in so much of a hurry, right,
to do something, that we forget to do it” (CO2-2012/13).
Across both time periods, prompts or systems to re-
mind staff to prescribe, administer or advise antenatal
magnesium sulphate were seen as important enablers for
increasing use. In 2011, several neonatologists and par-
ticularly obstetricians suggested benefits of ‘check-list
approaches’, and also visual reminders and signage (such
as posters in drug rooms and the labour ward, and
stamps or ‘alerts’ in the front of medical records):
“… a few more visual reminders… you know, kind of
‘Have you thought about?’ … If it’s in our face, we’ll
think about it. If it’s not, we’ll forget” (TO2-2011).
Similar suggestions were offered in 2012–13, however,
additionally, one consultant neonatologist and one con-
sultant obstetrician discussed possible benefits of deci-
sion support systems for prompting or reminding staff:
“…with the new EPAS [Enterprise Patient
Administration System]… the very sophisticated
electronic, medical notes systems… some of them have
automatic prompts… if you’ve admitted someone and
said, 28 weeks – da da da, ‘bung!’ – up would come,
you know, ‘have you considered mag sulphate for this
patient?’… So those sorts of prompts that sit behind
the system… it’s all about bringing it up and closing
the circle” (CN1-2012/13).
Environmental context and resources
This domain encompasses any circumstance of an indi-
vidual’s situation or environment that encourages or dis-
courages them to perform a task, including: resources
such as staff, materials, space, and competing time and
task constraints. Almost all participants across both time
periods highlighted barriers relating to the environment
or resources. Midwives and obstetricians in 2011 and
2012–13 discussed the difficulty of preparing and pre-
scribing the therapy as a barrier: “probably the main
barrier would be the complexity of the administration…
It’s not simple” (CO3-2012/13).
Issues around “having a separate line for it” and hav-
ing to “draw it all up” were described. Barriers relating
to administration were often discussed in the context of
time pressures surrounding imminent preterm birth.
One consultant obstetrician in 2012–13 expressed con-
cern that the time taken to prescribe magnesium
sulphate could deter junior staff:
“The doctor has got to write this very complicated set
of orders… So people will think “Oh, we just haven’t
got time. It’s too complicated, let’s just leave it, it’s just
too hard” you know?” (CO3-2012/13).
The main contextual barrier, however, recognised by
each professional group across both time periods, was
the unpredictability of preterm birth, and the speed at
which preterm labour can occur:
“Ah, I think the major barrier I’ve experienced is not
really knowing whether they are going to go into
labour or not and sometimes missing the opportunity
to start it, because preterm labour can happen so
quickly” (TO5-2011).
In recognition of the unpredictability of preterm birth
and the time taken to prepare magnesium sulphate for
administration, a frequent suggestion by midwives, and
also by obstetricians, across both time periods, was
“ready made” syringes:
“When we draw it up, you know it takes us at least
15 minutes… whereas if it’s already pre-done, amaz-
ingly quick! A pre-packed syringe or bag would be
great” (MW3-2012/13).
A desire for “more accurate ways of predicting preterm
deliveries” (TO3-2011) was expressed across both time
periods. The use of “more fetal fibronectin tests, which
doesn’t routinely happen” (TO2-2011) was suggested as a
potential facilitator by one trainee obstetrician in 2011.
Clear and concise, easily accessible guidelines and/or
protocols were highlighted by all professional groups,
particularly in 2011, as an enabler to timely and correct
administration. The potential benefits of incorporating
recommendations on use of antenatal magnesium
sulphate into a “prematurity guideline” (TN1-2011) or
“preterm labour protocol” (TN2-2012/13) were discussed
by two trainee neonatologists. In 2012–13, the need for
“the most user-friendly guideline” was highlighted, par-
ticularly in terms of monitoring, and the simplification
of the protocol was recognised as a facilitator:
“There were the two administration regimens… It is a
lot clearer now… It’s easier when there is just one
protocol and everyone sticks to it” (TO2-2012/13).
Other potential contextual or resource barriers, not as
commonly discussed across the two time periods,
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included “run[ning] out of magnesium sulphate a couple
of times” (MW5-2011) (one midwife, 2011), language
barriers (one neonatologist and one obstetrician, 2011;
one midwife, 2012–13), and distance, with women being
transferred from the country (one midwife, 2012–13).
Having “a stock of it on the labour ward” (CO4-2011)
was recognised by one obstetrician in 2011 as an enabler
to timely administration; with one trainee neonatologist
in 2011 noting “It needs to be easily available and I
think it is”. (TN1-2011).
In 2012–13, both midwives and obstetricians dis-
cussed, and highlighted as barriers, limitations surround-
ing magnesium sulphate administration being restricted
to the labour ward:
“There was really a bed block up in the delivery suite
on that day that prevented her from being transferred
immediately which is what we would usually do.
Instead, we were told “No, you’ve got to just keep her
on the antenatal ward”… So, that was somebody who
missed out.” (TO1-2012/13).
A lack of communication with the planning of preterm
birth between the antenatal and labour ward was also
discussed in 2012–13. To overcome such barriers, staff
suggested accrediting women’s assessment (emergency
service) and antenatal ward midwives to administer
magnesium sulphate, to allow the therapy to be given in
those service areas.
Beliefs about consequences
This theoretical domain includes an individual’s belief
about positive or negative consequences of providing an
intervention that may affect his or her behaviour. Staff
from each professional group, across both time periods,
discussed that an important enabler was the shared be-
liefs of health professionals and women that this therapy
could improve health outcomes for preterm born in-
fants. It was often discussed that despite potential side
effects for the mother, the ‘benefit-risk ratio’ was in
favour of treatment:
“I find that most women want to do the best by their
baby and if it’s talking about their brain, people want
to go ahead with it… Any drug that helps to reduce
complications of preterm birth is fantastic” (MW4-2011).
In 2012–13, one midwife suggested that women and
their partners’ uncertainty around “whether it’ll be of
benefit or risk” could serve as a potential barrier, and
identified the benefits of informing families of “any stats
that we’ve got regarding outcomes… That reassures them”
(MW7-2012/13).
One obstetrician in 2011 highlighted a belief of “not
enough hard evidence to support the use of antenatal mag-
nesium sulphate in terms of a good quality [randomised
controlled trial] for long term outcomes” (CO2-2011) as a
potential barrier, and believed that “more long term data
needs to be collected.” In 2012–13 however, one obstetrician
and one neonatologist expressed that while good quality
evidence existed, there was a need to continue to promote
it, due to the absence of immediately visible benefit:
“It doesn’t have an immediate benefit… you know, not
having cerebral palsy in two years’ time… you need to
convince them about the statistics and the odds”
(CN1-2012/13).
In 2011, beliefs of a number of obstetricians and one
neonatologist that magnesium sulphate could be associ-
ated with adverse effects or “toxicity” and concern re-
garding interactions with the tocolytic agent, nifedipine,
were recognised as potential barriers. In 2012–13, one
trainee obstetrician highlighted “poor tolerance of the treat-
ment by patients” (TO4-2012/13) as a possible barrier.
In 2012–13, one trainee obstetrician discussed that un-
certainly around timing of birth may lead to hesitation
in commencing treatment, especially in the context of
being held responsible or ‘blamed’ for potentially un-
necessary treatment:
“… there’s sometimes a culture of, um, blame almost if
you start magnesium you sort of get asked the next
day “Well, why did you start that? She hasn’t had a
baby”” (TO1-2012/13).
Social influences
This domain refers to the extent to which social influ-
ences, including peers and other professional groups, fa-
cilitate or hinder (or sometimes both) delivering an
intervention. In 2011, one trainee obstetrician discussed
that discrepancies between consultants’ opinions served
as a potential barrier to administration: “Sometimes they
say no, sometimes they say yes… so we are guided by that
as well” (TO4-2011).
Overwhelmingly, however, across both time periods,
staff from all professional groups cited supportive peers
as a key facilitator. Midwives highlighted senior staff
members, as useful “to clarify things with” (MW2-2011)
and particularly highlighted benefits of working with
registrars, with them being “really up to speed with it”
(MW8-2011). Midwives also highlighted their own ability
to influence colleagues:
“… working as a team… giving good feedback, to the
registrar saying like… “You know, do you think it’s,
would be, prudent to order it?”” (MW8-2011).
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Trainee obstetricians across both periods cited mid-
wives and consultant obstetricians as influential in guid-
ing their practice:
“The fact that the midwives are actually involved in
this helps a lot, so if I’ve forgotten, there’s always
someone prompting… The consultants are also aware
about it so they also, as we’re presenting our plans,
they also say “Hey, make sure it’s, it’s part of your
management plan”” (TO3-2012/13).
Senior obstetricians across both periods highlighted
positive influences particularly of junior obstetric staff
and midwives, but also of neonatologists:
“… the midwives in the labour ward are pretty good
on this, they’re on the ball… And the registrars are
too… they usually say well “Do you want the
magnesium sulphate with this baby?”… the
paediatricians are pretty good at it too” (CO2-2012/13).
One neonatologist in 2011 suggested that in order to
increase uptake you need “influential people pushing it…
someone to drive it along… putting some energy into
gaining that momentum” (CN1-2011), and proposed
nominating a dedicated obstetrician or midwife within
the hospital to serve as a ‘change champion’. Similarly, a
consultant neonatologist in 2012–13 recognised the ben-
efits of having “key people driving it” (CN1-2012/13).
A further enabler to increased use, recognised by one
neonatologist in 2011, were the NHMRC and Royal
Australian and New Zealand College of Obstetricians and
Gynaecologists (RANZCOG) endorsements of the guide-
lines: “pushing out these guidelines… as accepted best prac-
tice, in order for them to be extensively used” (CN3-2011).
Professional role and identity
This domain includes an individual’s perceptions about his
or her professional role or identity, and how these percep-
tions or beliefs influence the delivery of an intervention. In
2011, two trainees and two consultant neonatologists
described magnesium sulphate as an ‘obstetric medication’
with neonatal benefit, which could serve as a barrier “we
probably don’t push it as hard as we should” (CN1-2011).
In 2012–13, there was a similar recognition by some neo-
natologists that: “it’s mainly an obstetric decision” (TN2-
2012/13). Neonatologists in 2012–13 suggested that advis-
ing their colleagues to administer antenatal magnesium
sulphate was outside of their professional role:
“I do admit that it’s, it’s very likely a neonatologist will
deal with just the baby side of things and the timing of
delivery, and not perhaps be proactive about giving the
magnesium” (CN3-2012/13).
Reinforcement
This theoretical domain relates to factors that would
increase the probability of a response, such as rewards,
incentives or punishments. In 2011, one trainee and one
consultant neonatologist suggested that audit and feed-
back could serve as an enabler:
“I mean an audit cycle would be useful… see how
many were eligible and how many received it… and
using that as a basis to sort of re-educate people…
perhaps every single patient, that um, comes in, that is
eligible for NICU should, be prospectively audited…
“Yes? No? Why not?”” (TN1-2011).
In 2012–13, one neonatologist similarly suggested that an
enabler may be the development of a key performance indi-
cator (KPI) for institutions which could include the utilisa-
tion of new findings from clinical trials, such as regarding
antenatal magnesium sulphate for fetal neuroprotection.
The use of KPIs was likewise mentioned as a potential fa-
cilitator by one consultant neonatologist in 2011.
Two obstetricians in 2012–13 suggested incentives to
enable improved uptake; one trainee obstetrician
‘joked’ that appropriate administration of the therapy
could be “a requirement for getting onto the training pro-
gram” (TO2-2012/13). One consultant obstetrician rec-
ommended further involving and rewarding staff for
their participation in research work related to antenatal
magnesium sulphate:
“… you know, those sorts of things would be an added
incentive… Actually, include them in on the thing and
say, ok, you’re the key players in this, um, we want you
to be part of the paper… you’ll find that those people
will respond accordingly because it’s like waving a
carrot in front of them” (CO1-2012/13).
Discussion
Our study has provided valuable data on barriers and
enablers to evidence-based implementation of antenatal
magnesium sulphate for fetal neuroprotection, with a
number of key findings. First, self-reported use and
knowledge of this therapy appeared to increase over
time. Second, barriers were largely common across pro-
fessional groups and over time, and most often related
to the ‘environmental context and resources,’ with gaps
in ‘knowledge’ and ‘skills’ less common, particularly in
the later time period. Third, diverse enablers were iden-
tified by all professional groups which could be used to
change their and their colleagues’ practice.
In regards to self-reported administration or advice for
administration of antenatal magnesium sulphate, obstetri-
cians, neonatologists and midwives in 2012–13, compared
with in 2011, were more likely to report using/advising
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use in their clinical practice. While our study was not de-
signed to statistically compare use across time periods, the
apparent increase in self-reported use is supported by
quantitative findings from audit studies at our institution,
and others [25, 26], which have revealed, for example, an
increase in uptake from approximately 30 % in 2010 to al-
most 80 % in 2012–13 [22, 27].
Using the TDF proposed by Michie and colleagues
[17, 18], we assessed barriers and enablers to the use of
this therapy as perceived by health professionals. The
most significant barriers across both time periods
related to the domain ‘environmental context and re-
sources’, and included the difficulty to predict preterm
birth and the complex administration process, particu-
larly within the context of time pressures surrounding
unexpected or rapidly progressing preterm labour. In a
recent retrospective audit of ‘non-receipt’ of this ther-
apy at our institution, non-receipt was similarly deter-
mined to be associated most often with immediately
imminent or indicated emergent birth [27].
Not surprisingly, a common suggestion or enabler to
increase uptake was the use of pre-drawn syringes. The
use of ready-made solutions has importantly been recog-
nised as one strategy to reduce medication errors associ-
ated with magnesium sulphate [28]. In 2012–13, a
further facilitator to timely administration recognised by
a number of staff members was the expansion of the ser-
vice areas where magnesium sulphate could be safely
administered to include the women’s emergency service
and antenatal ward.
Other prominent barriers identified across both time
periods related to the domains ‘knowledge’ and ‘skills’
and ‘memory, attention, and decision processes’, includ-
ing: a lack of awareness of the guideline/protocol, un-
familiarity with the processes for administration, and
‘forgetting’. While lack of awareness was identified more
commonly as a barrier in 2011, across both time periods,
education was identified as an important enabler. How-
ever in 2012–13, an emphasis was placed on the need
for continued education for reinforcing knowledge, par-
ticularly in the context of frequent staff ‘turn-over’. To
overcome the barrier of not remembering, in 2011 par-
ticipants often suggested a need for visual reminders
(posters). In 2012–13, participants suggested using elec-
tronic support systems to aid in ‘flagging’ this treatment
for potentially eligible women.
A key enabler identified by participants across both
time periods (relating to the domain ‘beliefs about con-
sequences’) was staff and families’ belief in the ability for
this therapy to improve health outcomes. Arguably the
most significant enabler discussed by all professional
groups, however, was the support from other staff mem-
bers (associated with the ‘social influences’ domain). All
professional groups – midwives, obstetric trainees and
consultants, and neonatal trainees and consultants –
were recognised by their colleagues as having influential
roles in guiding practice and facilitating the delivery of
this intervention.
Our study highlighted barriers and enablers that were
both common and differing across two time periods. It
is possible that some of the changes over time in per-
ceived barriers/enablers can be partially attributed to the
availability of WISH materials following the first phase
of interviews – including posters that were displayed in
delivery suite, antenatal ward and emergency service
areas, health professional information sheets that were
widely distributed, and in-service sessions that were
regularly held [15]. Certainly, increased awareness of the
guidelines was observed in the second time period, when
participants focused on the need to reinforce knowledge
along with other new approaches to increase uptake.
WISH Project strategies have also included the identifi-
cation of a local ‘clinical champion’ at our institution,
whose role has been to offer support to and advise col-
leagues [15]. Encouragingly, participants in this study
discussed the importance of such leaders to drive imple-
mentation and act as a ‘catalyst’.
Our study had some limitations. Firstly, study partici-
pants were recruited from only one tertiary maternity
centre in South Australia. Additional barriers and en-
ablers may exist in other settings and locations, which
would be important to identify if developing tailored in-
terventions for addressing evidence-practice gaps [17].
However, many of the barriers and enablers (and corre-
sponding theoretical domains) identified in our study are
likely to be common, and thus our findings are useful to
health professionals in other maternity centres wishing
to improve the use of this neuroprotective treatment for
very preterm infants.
Secondly, the number of health professionals inter-
viewed in each group of our study was somewhat arbi-
trarily pre-specified; and in the second time period, we
had fewer participants than expected. However, as no
new information was forthcoming, we believe data satur-
ation was achieved. Interviews with women at risk of
very preterm birth, reception/administration staff, and
staff working at common referral hospitals, would, how-
ever also provide valuable data, and these groups could
be the subject of additional research.
Finally, we did not, as some previous barrier and en-
abler exploration studies have done [19, 21], use the
TDF to guide the interview schedule, and individual
questions were not framed in order to explore each do-
main of the framework individually. The TDF, used dur-
ing the coding/analysis stage, was valuable, with benefits
of using the framework including the efficiency with
which the interview data could be coded. We also be-
lieve that the open-ended nature of relevant questions in
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this study should not have biased barriers/enablers from
any particular domain emerging.
Conclusions
Our study, using the TDF, has provided valuable data on
barriers and enablers to evidence-based implementation
of antenatal magnesium sulphate for fetal neuroprotec-
tion as perceived by obstetricians, neonatologists and
midwives. Health professionals identified difficulty in
predicting preterm birth, which may be precipitous or
immediately imminent, within the context of time con-
straints and complex administration procedures as key
barriers. Regarding enablers to implementation, partici-
pants commonly suggested education, reminders, audit
and feedback, decision-support systems, expanding the
range of services areas, pre-prepared syringes, and sup-
port from colleagues or influential individuals. Results of
this study will guide the planning and modification of
further implementation strategies with the goal of im-
proving neuroprotection for very preterm infants. We
encourage research into barriers and enablers in differ-
ence settings; some may prove common and others may
be setting specific. Seeking pregnant women’s views of
barriers and enablers to use of magnesium sulphate for
neuroprotection is also important.
Additional files
Additional file 1: Summary of clinical recommendations for
antenatal magnesium sulphate prior to preterm birth for
neuroprotection of the fetus, infant and child. (PDF 80 kb)
Additional file 2: Interview schedule. (PDF 243 kb)
Abbreviations
NHMRC: National Health and Medical Research Council; TDF: Theoretrical
Domains Framework; WCH: Women's and Children's Hospital; WISH: Working
to Improve Survival and Health for babies born very preterm.
Competing interests
CAC was the principal investigator for the Australasian Collaborative Trial
of Magnesium Sulphate (ACTOMgSO4). CAC and PM are authors of the
Cochrane review ‘Magnesium sulphate for women at risk of preterm birth
for neuroprotection of the fetus.’ CAC, PM and TB were members of the
Guideline Development Panel, for the NHMRC endorsed ‘Antenatal
magnesium sulphate prior to preterm birth for neuroprotection of the fetus,
infant and child: National clinical practice guidelines.’ The authors declare
that they have no other competing interests.
Authors’ contributions
CAC and PM conceived the study. EB, TB, EVR, LS and SR carried out the
interviews and EB and TB analysed the results. EB and TB drafted the
manuscript. All authors revised the manuscript for important intellectual
content and take public responsibility for its content. All authors read and
gave final approval of the version to be published.
Acknowledgements
The WISH Project is funded by a Cerebral Palsy Alliance Research Foundation
Innovative Research Grant (IGR-2010-CR). The Research Foundation was not
involved in, and did not influence, data collection or analysis, the writing or
submission of this manuscript.
Author details
1Australian Research Centre for Health of Women and Babies, Robinson
Research Institute, Discipline of Obstetrics and Gynaecology, School of
Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
2The Women’s and Children’s Hospital, North Adelaide, South Australia,
Australia. 3Liggins Institute, The University of Auckland, Auckland, New
Zealand.
Received: 7 January 2015 Accepted: 10 August 2015
References
1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of
preterm birth. Lancet. 2008;371(9606):75–84.
2. Saigal S, Doyle L. An overview of mortality and sequelae of preterm birth
from infancy to adulthood. Lancet. 2008;371(9608):261–9.
3. Australian Cerebral Palsy Register Group: Report of the Australian Cerebral
Palsy Register, Birth Years 1993–2006. Cerebral Palsy Alliance Research
Institute. Sydney; 2013.
4. McIntyre S, Novak I, Cusick A. Consensus research priorities for cerebral
palsy: a Delphi survey of consumers, researchers, and clinicians. Dev Med
Child Neurol. 2010;52(3):270–5.
5. Nelson KB, Grether JK. Can magnesium sulphate reduce the risk of cerebral
palsy in very low birthweight infants? Paediatr. 1995;95(2):263–9.
6. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate
given for neuroprotection before preterm birth: a randomized controlled
trial. JAMA. 2003;290:2669–76.
7. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, et al.
Magnesium sulphate given before very-preterm birth to protect infant
brain: the randomised controlled PREMAG trial. Br J Obstet Gynaecol.
2007;114:310–8.
8. Mittendorf R, Dambrosia J, Pryde PG, Lee K-S, Gianopoulos JG, Besinger RE,
et al. Association between the use of antenatal magnesium sulfate in
preterm labor and adverse health outcomes in infants. Am J Obstet
Gynecol. 2002;186:1111–8.
9. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A
randomized, controlled trial of magnesium sulfate for the prevention of
cerebral palsy. N Engl J Med. 2008;359:895–905.
10. Magpie Trial Follow-Up Study Collaborative Grou. The Magpie Trial: a
randomised trial comparing magnesium sulphate with placebo for
pre-eclampsia. Outcome for children at 18 months. Br J Obstet Gynaecol.
2007;114:289–99.
11. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse DJ. Magnesium
sulphate for women at risk of preterm birth for neuroprotection of the
fetus. Cochrane Database Syst Rev. 2009;1, CD004661. doi:10.1002/
14651858.CD004661.pub3.
12. Antenatal Magnesium Sulphate for Neuroprotection Guideline
Development Panel. Antenatal magnesium sulphate prior to preterm birth
for neuroprotection of the fetus, infant and child: National clinical practice
guidelines. Adelaide: The University of Adelaide; 2010.
13. Mugford M. Corticosteroids in preterm delivery-estimated impact on
neonatal outcomes and health service resources. In: A review of stillbirths
and neonatal mortality in the Oxford Region. Oxford: Oxford Regional
Health Authority; 1993. p. 37–40.
14. Penney G, Foy R. Do clinical guidelines enhance safe practice in obstetrics
and gynaecology? Best Pract Res Clin Obstet Gynaecol. 2007;21(4):657–73.
15. Crowther CA, Middleton PF, Bain E, Ashwood P, Bubner T, Flenady V, et al.
Working to improve survival and health for babies born very preterm: the
WISH project protocol. BMC Pregnancy Childbirth. 2013;13:239.
16. Chaillet N, Dube E, Dugas M, Audibert F, Tourigny C, Fraser WD, et al.
Evidence-based strategies for implementing guidelines in obstetrics: a
systematic review. Obstet Gynecol. 2006;108(5):1234–45.
17. Cane J, O’Connor D, Michie S. Validation of the theoretical domains
framework for use in behaviour change and implementation research.
Implement Sci. 2012;7:37.
18. Michie S, Johnson M, Abraham C, Lawton R, Parker D, Walker A, et al.
Making psychological theory useful for implementing evidence based
practice: a consensus approach. BMC Pregnancy Childbirth. 2005;14(1):26–33.
19. Mazza D, Chapman A, Michie S. Barriers to the implementation of
preconception care guidelines as perceived by general practitioners:
a qualitative study. BMC Health Serv Res. 2013;13:36.
Bain et al. BMC Pregnancy and Childbirth  (2015) 15:176 Page 10 of 11
20. Heslehurts N, Newham J, Maniatopoulos G, Fleetwood C, Robalino S,
Rankin J. Implementation of pregnancy weight management and obesity
guidelines: a meta-analysis of healthcare professionals’ barriers and
facilitators using the Theoretical Domains Framework. Obes Rev.
2014;15(6):462–86.
21. Beenstock J, Sneihotta FF, White M, Bell R, Milne EM, Araujo-Soares V. What
helps and hinders midwives in engaging with pregnant women about
stopping smoking? A cross-sectional survey of perceived implementation
difficulties among midwives in the North East of England. Implement Sci.
2012;7:36.
22. Bain E, Ashwood P, Middleton PF, Bubner T, Heatley E, Zhang Y, et al. Rapid
implementation of antenatal magnesium sulphate for fetal neuroprotection
at the WCH, Adelaide, Australia (2009–2012). J Paediatr Child Health. 2013;49
Suppl 2:OP036.
23. Women’s and Children’s Health Network: Women’s and Children’s Hospital.
http://www.wch.sa.gov.au/ (2005). Accessed 29 Jun 2015.
24. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing
qualitative data. BMJ. 2000;320(7227):114–6.
25. Mills CE, Beckmann M, Flenady V, Bain E, Middleton P, Crowther CA. for the
WISH Study Team. Implementing the bi-national guidelines on antenatal
magnesium sulphate for fetal neuroprotection: factors influencing
compliance at a large tertiary centre. J Paediatr Child Health.
2014;50 Suppl 1:S394.
26. Ow LL, Kennedy A, McCarthy EA, Walker SP. Feasibility of implementing
magnesium sulphate for neuroprotection in a tertiary obstetric unit.
Aust N Z J Obstet Gynaecol. 2012;52(4):356–60.
27. Siwicki K, Bain E, Ashwood P, Bubner T, Middleton P, Crowther CA. “There
aren’t too many that get away, are there?” Non-receipt of antenatal
magnesium sulphate for fetal neuroprotection at the Women’s and
Children’s Hospital, Adelaide 2010–13. J Paediatr Child Health.
2014;50 Suppl 1:A401.
28. Simpson KR, Knox GE. Obstetrical accidents involving intravenous
magnesium sulfate: recommendations to promote patient safety.
MCN Am J Matern Child Nurs. 2004;29:161–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bain et al. BMC Pregnancy and Childbirth  (2015) 15:176 Page 11 of 11
